<DOC>
	<DOCNO>NCT00004333</DOCNO>
	<brief_summary>OBJECTIVES : Assess whether 2- ( 2-nitro-4-trifluoromethylbenzoyl ) -1,3-cyclohexanedione ( NTBC ) 0.6 mg/kg per day prevents liver failure least 1 patient tyrosinemia type I .</brief_summary>
	<brief_title>Phase II Study Enzyme Inhibitor NTBC Tyrosinemia Type I</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Only 2 patient tyrosinemia type I know research team ; others treat found clinical condition permit . The enzyme inhibitor 2- ( 2-nitro-4-trifluoromethylbenzoyl ) -1,3-cyclohexanedione ( NTBC ) administer orally , 2 divide dos daily meal . Patients follow closely side effect attributable NTBC .</detailed_description>
	<mesh_term>Tyrosinemias</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Tyrosinemia type I No cirrhosis No hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>inborn error metabolism</keyword>
	<keyword>rare disease</keyword>
	<keyword>tyrosinemia I</keyword>
</DOC>